- Founded
- 2022
- Employees
- 5
- Total Funding
- $25M
Founded by Karl Deisseroth, Xiao Wang, Ye Fu in 2022.
About Stellaromics
Founded in 2022 and headquartered in Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations. Stellaromics is currently in the advanced stages of developing its Plexa™ suite of products, meticulously crafted to empower researchers and clinicians in the creation of intricate cellular maps, thereby amplifying our comprehension of various diseases. For comprehensive details, we invite you to explore our website at stellaromics.com. Join us in shaping the future of biomedical research.
Leadership at Stellaromics
The team at the top of the org chart.
Todd Dickinson
Chief Executive Officer
25 reports
Ye Fu
Chief Scientific Officer And Co-founder
9 reports
Gerrit C Smith
Senior Vice President Product Development & Operations
7 reports
Mark Pratt
Chief Technology Officer
3 reports
Christopher Payton
Fractional CFO
1 report
Hannah Huelin-Meek
Head of People